This suggests that inhibition of KRAS or autophagy may sensitize CRC cells harboring KRAS mutations to cancer therapies, reinforcing KRAS-induced autophagy inhibition as an emerging target for CRC therapeutic approaches. The gene discussed is KRAS; the disease is colorectal carcinoma.